Vivek Subbiah: Delighted to publish our editorial. TRKing sarcomas for precision medicine: Seek, and ye shall find! In the American Cancer Society Journal Cancer.

Vivek Subbiah, Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute, shared on X/Twitter:

”Hot off the press. Delighted to publish our editorial. TRKing sarcomas for precision medicine: Seek, and ye shall find! In the American Cancer Society Journal Cancer. We included a plain language summary so everyone can read. The way in which we treat different types of cancer has changed a lot because of genome-driven precision oncology. This approach uses information from a person’s genes to personalize their treatment. A recent study conducted confirms that neurotrophic receptor tyrosine kinase (NTRK) inhibitors are beneficial in treating sarcomas with NTRK fusions Precision Medicine for the win.”

For the article click here.
Source: Vivek Subbiah/Twitter